SQZ Biotechnologies accepted by Roche Accelerator in China

By The Science Advisory Board staff writers

December 3, 2021 -- SQZ Biotechnologies, a clinical-stage cell therapy biotechnology company that develops treatments for patients with cancer, infectious diseases, and autoimmune conditions, announced that its SQZ China Initiative has been accepted by the Roche Accelerator in China.

Roche's accelerator is the company's first in-house global accelerator and further establishes its long-term commitment to Shanghai and China. Embedded in the Roche R&D organization, the accelerator empowers entrepreneurs to bridge the gap between concept and proof of concept. Roche provides seed funding, support through intensive coaching and guidance, physical infrastructure and operations, and flexibility tailored to each entrepreneur.

China's healthcare ecosystem is of growing global importance and offers significant opportunities for patient impact, SQZ Biotech said. Collaborating with the Roche Accelerator will support SQZ Biotech's early strategic planning, market exploration, and potential China-based activities for the SQZ China Initiative.

"We are excited to be one of the first members of the Roche Accelerator and to begin working with its talented experts to support strategic planning for this important global healthcare center," Armon Sharei, PhD, chief executive officer and founder of SQZ Biotechnologies, said.

Roche and SQZ Biotech have been strategic partners since 2015. Roche has an ongoing collaboration on the SQZ antigen-presenting cell oncology platform globally.

Roche releases genomic profiling kit for cancer research
Roche has released a new genomic profiling kit for cancer research called the Avenio Tumor Tissue Comprehensive Genomic Profiling kit.
How one company aims to make bedside cell therapies a reality
SQZ Biotech is developing high-throughput technology that can manufacture novel cell therapy products in under 24 hours. Founder and CEO Armon Sharei,...
Adaptimmune collaborates with Genentech on allogeneic T-cell therapies
Adaptimmune Therapeutics is joining forces with Genentech, a Roche company, to develop and commercialize allogeneic T-cell therapies for multiple oncologic...
Personalized cell therapies offer hope for some of the toughest cancers
Complete with a long-term vision of developing a pipeline of oncology therapies that modulate the functional immune system, Sotio of the Czech Republic...
Roche becomes founding partner of biotech accelerator
Roche has become a founding partner in the second phase of development of BaseLaunch, a Basel, Switzerland-based incubator and accelerator that helps...

Copyright © 2021 scienceboard.net

International Paper Physics Conference 2023 (IPPC2023)
May 31 - June 2
Guangzhou, Guangdong China
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter